News

  • 19 July 2019

    UK’s NICE backs Novartis breast cancer drug Kisqali

    The UK’s National Institute for Health and Care Excellence (NICE) has approved Novartis’ drug Kisqali (ribociclib) in combination with fulvestrant for the treatment of certain patients with advanced breast cancer.

  • 17 July 2019

    Gotham and Mercachem generate epitranscriptomic target library

    New York-based RNA-focused drug discovery company Gotham Therapeutics and German contract research organization (CRO) Mercachem have announced they have created a high-quality compound library focused on epitranscriptomic drug discovery.

Close
Close
Close

Go Top